Shots:

• The companies collaborated to conduct the clinical studies of a dual regimen consisting of Ascentage’s APG-2575 and Henlius’s HLX01 (biosimilar- rituximab) for the treatment of chronic lymphocytic leukemia in the People's Republic of China
• The teams from both the companies will explore the clinical utility of the dual regimen aiming to demonstrate a synergistic effect in the treatment of CLL- offering an additional treatment option to patients in China
• Ascentage’s APG-2575 is a Bcl-2 selective inhibitor- act by restoring apoptosis process in cancer cells while Henlius’s HLX01 is the first approved biosimilar in China indicated to treat non-Hodgkin's lymphoma

Click here to­ read full press release/ article | Ref: PRnewswire | Image: Yahoo News Singapore